首页> Current oncology (Toronto, Ont.)> Conditional approval of cancer drugs in Canada: accountability and impact on public funding.

Conditional approval of cancer drugs in Canada: accountability and impact on public funding.

导出 OA

翻译打印收藏纠错

第一作者： S K,Andersen

第一单位： Department of Medicine, University of Toronto, Toronto, ON.

作者： S K,Andersen ^[1] ; N,Penner ^[2] ; A,Chambers ^[2] ; M E,Trudeau ^[3] ; K K W,Chan ^[4] ; M C,Cheung ^[5]

作者单位： Department of Medicine, University of Toronto, Toronto, ON. ^[1] pan-Canadian Oncology Drug Review, Canadian Agency for Drugs and Technologies in Health, Ottawa, ON. ^[2] Canadian Centre for Applied Research in Cancer Control, Toronto, ON.;Department of Medicine, University of Toronto, Toronto, ON.;Division of Hematology and Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON. ^[3] Department of Medicine, University of Toronto, Toronto, ON.;pan-Canadian Oncology Drug Review, Canadian Agency for Drugs and Technologies in Health, Ottawa, ON.;Division of Hematology and Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON. ^[4] Department of Medicine, University of Toronto, Toronto, ON.;Division of Hematology and Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON. ^[5]

关键词 Health Canada Medical oncology health economics health policy pcodr

医学主题词抗肿瘤药(Antineoplastic Agents);加拿大(Canada);费用效益分析(Cost-Benefit Analysis);人类(Humans);医学肿瘤学(Medical Oncology);肿瘤(Neoplasms);社会责任(Social Responsibility)

DOI 10.3747/co.26.4397

PMID 30853815

发布时间 2020-03-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交